The agenda features a mix of clinical updates and lively debates on provocative scientific topics in the field.

Agenda

November 1-2 | Nashville

Available DatesRegister

May 3-4 | New York City

November 1-2 | Nashville

Friday November 01, 2024

8:00 AM – 8:05 AM
Welcome
- Co-Chair
  - Erika HamiltonMD
8:05 AM – 8:20 AM
Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - YES
- Presenter
  - Tiffany TrainaMD, FASCO
8:20 AM – 8:35 AM
Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - NO
- Presenter
  - Melinda TelliMD, FASCO
8:35 AM – 8:45 AM
Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - DISCUSSION
- Moderator
  - Erika HamiltonMD
- Panelist
  - Melinda TelliMD, FASCO
  - Tiffany TrainaMD, FASCO
8:45 AM – 9:00 AM
Debate: Antibody Drug Conjugates as the New Frontier: Should We Use Them Sequentially? - Yes, They Are Better than Chemo
- Presenter
  - Kelly McCannMD, PhD
9:00 AM – 9:15 AM
Debate: Antibody Drug Conjugates as the New Frontier: Should We Use Them Sequentially? - No, the Benefit Is Really Just for the First ADC
- Presenter
  - Denise YardleyMD
9:15 AM – 9:25 AM
Debate: Antibody Drug Conjugates as the New Frontier: Should We Use Them Sequentially? - DISCUSSION
- Moderator
  - Erika HamiltonMD
- Panelist
  - Denise YardleyMD
  - Kelly McCannMD, PhD
9:25 AM – 9:35 AM

Break
9:35 AM – 10:35 AM

Non-CME Innovation Theater - Sponsored by Pfizer
10:35 AM – 11:15 AM

Case Discussions
11:15 AM – 11:30 AM
Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - YES
- Presenter
  - Seth WanderMD, PhD
11:30 AM – 11:45 AM
Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - NO
- Presenter
  - Adam BrufskyMD, PhD
11:45 AM – 11:55 AM
Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - DISCUSSION
- Moderator
  - Erika HamiltonMD
- Panelist
  - Adam BrufskyMD, PhD
  - Seth WanderMD, PhD
11:55 AM – 12:05 PM

Break
12:05 PM – 1:05 PM

Non-CME Innovation Theater - Sponsored by Pfizer
1:05 PM – 1:35 PM

Exhibit Hall
1:35 PM – 1:50 PM
Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? - Locally Advanced Cervical Cancer
- Presenter
  - Leslie RandallMD
1:50 PM – 2:05 PM
Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? – In Combination with Chemotherapy in the First-Line Metastatic Setti
- Presenter
  - Trey LeathMD, MSPH
2:05 PM – 2:15 PM
Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? - DISCUSSION
- Moderator
  - Kathleen MooreMD, MS
- Panelist
  - Leslie RandallMD
  - Trey LeathMD, MSPH
2:15 PM – 2:55 PM
Case Discussions
- Moderator
  - Kathleen MooreMD, MS
- Panelist
  - Angeles SecordMD, MHSc
  - Erin CraneMD, MPH
  - Leslie RandallMD
  - Linda DuskaMD, MPH
  - Matthew PowellMD
  - Trey LeathMD, MSPH
2:55 PM – 3:05 PM

Break
3:05 PM – 4:05 PM

Non-CME Innovation Theater - Sponsored by AstraZeneca
4:05 PM – 4:20 PM
Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? – Platinum is the SOC
- Presenter
  - Linda DuskaMD, MPH
4:20 PM – 4:35 PM
Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? – It's Time to Move on From Platinum
- Presenter
  - Angeles SecordMD, MHSc
4:35 PM – 4:45 PM
Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? Platinum is the SOC vs It's Time to Move on From Platinum - DISCUSSION
- Moderator
  - Kathleen MooreMD, MS
- Panelist
  - Angeles SecordMD, MHSc
  - Linda DuskaMD, MPH
4:45 PM – 5:00 PM
Debate: Immune-Checkpoint Inhibitors Should Be Used: With and to Follow Chemotherapy in All Patients with Advanced Endometrial Cancer - Irrespective of Biomarker
- Presenter
  - Erin CraneMD, MPH
5:00 PM – 5:15 PM
Debate: Immune-Checkpoint Inhibitors Should Be Used: Only in dMMR in the Front Line. pMMR Should Receive in Recurrent Setting with Lenvatinib Based On OS Advantage
- Presenter
  - Matthew PowellMD
5:15 PM – 5:25 PM
Debate: Immune-Checkpoint Inhibitors Should Be Used: With and to Follow Chemotherapy in All Patients with Advanced Endometrial Cancer - Irrespective of Biomarker vs Only in dMMR in the Front Line. pMMR Should Receive In Recurrent Setting with Lenvatinib
- Panelist
  - Erin CraneMD, MPH
  - Matthew PowellMD

Saturday November 02, 2024

8:00 AM – 8:05 AM
Welcome
- Co-Chair
  - Erika HamiltonMD
8:05 AM – 8:20 AM
Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - YES
- Presenter
  - Letícia VarellaMD
8:20 AM – 8:35 AM
Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - NO
- Presenter
  - Denise YardleyMD
8:35 AM – 8:45 AM
Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - DISCUSSION
- Moderator
  - Erika HamiltonMD
- Panelist
  - Denise YardleyMD
  - Letícia VarellaMD
8:45 AM – 9:00 AM
Debate: Should We Now Be Screening for HER-2 Brain Mets? - YES
- Presenter
  - Katarzyna JerzakMD, MSc, FRCPC
9:00 AM – 9:15 AM
Debate: Should We Now Be Screening for HER-2 Brain Mets? - NO
- Presenter
  - Laura HuppertMD
9:15 AM – 9:25 AM
Debate: Should We Now Be Screening for HER-2 Brain Mets? - DISCUSSION
- Moderator
  - Erika HamiltonMD
- Panelist
  - Katarzyna JerzakMD, MSc, FRCPC
  - Laura HuppertMD
9:25 AM – 9:35 AM

Break
9:35 AM – 10:35 AM

Non-CME Innovation Theater - Sponsored by Daiichi Sankyo/AstraZeneca
10:35 AM – 11:05 AM

Exhibit Hall
11:05 AM – 11:45 AM
HR+/HER2- Metastatic Breast Cancer: Addressing Unmet Needs and Endocrine Therapy Resistance in Frontline Treatment
- Presenter
  - Janice LuMD, PhD
11:45 AM – 12:00 PM
Debate: HER-2 Low: Should We Even Test? - Yes, Expression Matter
- Presenter
  - Paolo TarantinoMD
12:00 PM – 12:15 PM
Debate: HER-2 Low: Should We Even Test? - No, So Little Expression is Required We Shouldn’t
- Presenter
  - Demetria Smith-GrazianiMD, MPH
12:15 PM – 12:25 PM
Debate: HER-2 Low: Should We Even Test? - DISCUSSION
- Moderator
  - Erika HamiltonMD
- Panelist
  - Demetria Smith-GrazianiMD, MPH
  - Paolo TarantinoMD
12:25 PM – 12:35 PM

Break
12:35 PM – 1:35 PM

Non-CME Innovation Theater - Sponsored by Novartis
1:35 PM – 2:15 PM
Addressing the Spectrum of Platinum-Resistant Ovarian Cancer: Newer and Emerging Targeted Therapies
- Presenter
  - Ursula MatulonisMD
2:15 PM – 2:30 PM
Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: Everyone Should Be Offered PARPi
- Presenter
  - Thomas HerzogMD
2:30 PM – 2:45 PM
Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: New Opportunities Beyond PARPi
- Presenter
  - R. NaumannMD
2:45 PM – 2:55 PM
Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: Everyone Should Be Offered PARPi vs. New Opportunities Beyond PARPi – DISCUSSION
- Moderator
  - Kathleen MooreMD, MS
- Panelist
  - R. NaumannMD
  - Thomas HerzogMD
2:55 PM – 3:10 PM

Break
3:10 PM – 3:25 PM
Advancements in the Treatment of Front-Line Endometrial Cancer
- Presenter
  - Floor BackesMD
3:25 PM – 3:40 PM
Recurrent Endometrial Cancer: New Opportunities to Prolong Survival
- Presenter
  - Christina WashingtonMD
3:40 PM – 3:50 PM
Q&A Panel
- Moderator
  - Kathleen MooreMD, MS
- Panelist
  - Christina WashingtonMD
  - Floor BackesMD
3:50 PM – 4:05 PM
Paradigm Changes and New Opportunities to Treat Low Grade Serous Ovarian Cancer
- Presenter
  - Lauren CobbMD
4:05 PM – 4:20 PM
ADC Abundance: Leveraging Other Solid Tumor Experience to Guide Development of Sequencing and Biomarkers in Gynecologic Cancers
- Presenter
  - Kathleen MooreMD, MS
4:20 PM – 4:30 PM
Q&A Panel
- Moderator
  - Kathleen MooreMD, MS
- Panelist
  - Lauren CobbMD

Available Dates

Agenda

November 1-2 | Nashville

Friday November 01, 2024

Welcome

Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - YES

Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - NO

Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - DISCUSSION

Debate: Antibody Drug Conjugates as the New Frontier: Should We Use Them Sequentially? - Yes, They Are Better than Chemo

Debate: Antibody Drug Conjugates as the New Frontier: Should We Use Them Sequentially? - No, the Benefit Is Really Just for the First ADC

Debate: Antibody Drug Conjugates as the New Frontier: Should We Use Them Sequentially? - DISCUSSION

Break

Non-CME Innovation Theater - Sponsored by Pfizer

Case Discussions

Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - YES

Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - NO

Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - DISCUSSION

Break

Non-CME Innovation Theater - Sponsored by Pfizer

Exhibit Hall

Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? - Locally Advanced Cervical Cancer

Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? – In Combination with Chemotherapy in the First-Line Metastatic Setti

Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? - DISCUSSION

Case Discussions

Break

Non-CME Innovation Theater - Sponsored by AstraZeneca

Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? – Platinum is the SOC

Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? – It's Time to Move on From Platinum

Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? Platinum is the SOC vs It's Time to Move on From Platinum - DISCUSSION

Debate: Immune-Checkpoint Inhibitors Should Be Used: With and to Follow Chemotherapy in All Patients with Advanced Endometrial Cancer - Irrespective of Biomarker

Debate: Immune-Checkpoint Inhibitors Should Be Used: Only in dMMR in the Front Line. pMMR Should Receive in Recurrent Setting with Lenvatinib Based On OS Advantage

Debate: Immune-Checkpoint Inhibitors Should Be Used: With and to Follow Chemotherapy in All Patients with Advanced Endometrial Cancer - Irrespective of Biomarker vs Only in dMMR in the Front Line. pMMR Should Receive In Recurrent Setting with Lenvatinib

Saturday November 02, 2024

Welcome

Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - YES

Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - NO

Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - DISCUSSION

Debate: Should We Now Be Screening for HER-2 Brain Mets? - YES

Debate: Should We Now Be Screening for HER-2 Brain Mets? - NO

Debate: Should We Now Be Screening for HER-2 Brain Mets? - DISCUSSION

Break

Non-CME Innovation Theater - Sponsored by Daiichi Sankyo/AstraZeneca

Exhibit Hall

HR+/HER2- Metastatic Breast Cancer: Addressing Unmet Needs and Endocrine Therapy Resistance in Frontline Treatment

Debate: HER-2 Low: Should We Even Test? - Yes, Expression Matter

Debate: HER-2 Low: Should We Even Test? - No, So Little Expression is Required We Shouldn’t

Debate: HER-2 Low: Should We Even Test? - DISCUSSION

Break

Non-CME Innovation Theater - Sponsored by Novartis

Addressing the Spectrum of Platinum-Resistant Ovarian Cancer: Newer and Emerging Targeted Therapies

Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: Everyone Should Be Offered PARPi

Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: New Opportunities Beyond PARPi

Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: Everyone Should Be Offered PARPi vs. New Opportunities Beyond PARPi – DISCUSSION

Break

Advancements in the Treatment of Front-Line Endometrial Cancer

Recurrent Endometrial Cancer: New Opportunities to Prolong Survival

Q&A Panel

Paradigm Changes and New Opportunities to Treat Low Grade Serous Ovarian Cancer

ADC Abundance: Leveraging Other Solid Tumor Experience to Guide Development of Sequencing and Biomarkers in Gynecologic Cancers

Q&A Panel

Questions?